The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.

Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.

The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.

Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.